Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer: Treatment description and preliminary results of a phase I/II clinical trial
- William Beaumont Hospital, Royal Oak, MI (United States); and others
To improve results for locally advanced prostate cancer, a prospective clinical trial of concurrent external beam irradiation and fractionated iridium-192 (IR-192) high dose rate (HDR) conformal boost brachytherapy was initiated. This technique of concurrent external pelvic irradiation and conformal HDR brachytherapy was well tolerated. No significant intraoperative or perioperative complications occurred. Three patients (9%) experienced Grade 3 acute toxicity (two dysuria and one diarrhea). All toxicities were otherwise Grades 1 or 2 and were primarily as expected from pelvic external irradiation. Persistent implant-related toxicities included Grades 1-2 perineal pain (12%) and hematospermia (15%). Median follow-up time was 13 months. Serum prostatic-specific antigen (PSA) levels normalized in 91% of patients (29 out of 32) within 1-14 months (median 2.8 months) after irradiation. PSA levels were progressively decreasing in the other three patients at last measurement. Prospectively planned prostatic rebiopsies done at 18 months in the first 10 patients were negative in 9 out of 10 (90%). Acute toxicity has been acceptable with this unique approach using conformal high dose rate IR-192 boost brachytherapy with concurrent external irradiation. The initial tumor response as assessed by serial PSA measurement and rebiopsy is extremely encouraging. Dose escalation will proceed in accordance with the protocol guidelines. Further patient accrual and longer follow-up will allow comparison to other techniques. 58 refs., 5 figs., 4 tabs.
- OSTI ID:
- 430960
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 33, Issue 1; Other Information: PBD: 30 Aug 1995
- Country of Publication:
- United States
- Language:
- English
Similar Records
High-Dose-Rate Brachytherapy as a Monotherapy for Favorable-Risk Prostate Cancer: A Phase II Trial
Implementation of High-Dose-Rate Brachytherapy and Androgen Deprivation in Patients With Prostate Cancer